FGFR2 and congenital rubella syndrome: These panels could achieve 28%–52% diagnostic yield for CRS patients, but the good performance was limited in core CRS genes, such as FGFR2, FGFR3, ERF, TWIST1, TCF12, and EFBN1 (Wilkie et al., 2010; Roscioli et al., 2013; Paumard-Hernandez et al., 2015; Wilkie et al., 2017; Lee et al., 2018; Yoon et al., 2020; Wu et al., 2021).